ABT
Status-Quo-PlayerAbbott Laboratories
$100.69
+0.42%
as of 13 Apr
Power Core
Moat: Abbott's moat is its ability to embed recurring revenue models inside product categories where competitors still sell discrete units.
Direction of Movement
Libre-Led Growth With Device Pipeline Reaching Inflection
ROC 200
-23.2%
ABT
Abbott Laboratories
$100.69
+0.42%
as of 13 Apr
DCF Fair Value: $129.90
Market data unavailable
Company Profile
Abbott Laboratories is a diversified global healthcare company that discovers, develops, manufactures, and sells a broad portfolio of health care products worldwide. It operates across four key segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices, addressing needs from chronic disease management to acute diagnostics. The company offers generic pharmaceuticals treating conditions such as pancreatic exocrine insufficiency, irritable bowel syndrome, dyslipidemia, hypertension, hypothyroidism, pain, fever, inflammation, and migraine, alongside anti-infectives, influenza vaccines, and gastrointestinal regulators. Notable products include cardiovascular devices like pacemakers and stents, diabetes management tools such as continuous glucose monitors, pediatric and adult nutritional formulas, and advanced diagnostic equipment like immunoassays and point-of-care testing kits. With approximately 114,000 employees and a history dating back to 1888, Abbott Laboratories generates the majority of its sales outside the United States, playing a pivotal role in advancing medical innovation, improving patient outcomes, and supporting global health initiatives through its extensive reach in consumer, institutional, and professional markets.